Cadila Healthcare gets USFDA approval:

Cadila

Zydus Cadila has received final approval from the USFDA to market Ibrutinib Capsules, 70 mg and 140 mg, company said in the release to the exchange.

Ibrutinib belongs to a class of drugs known as kinase inhibitors and is used to treat certain cancers, such as mantle cell lymphoma or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and Waldenstrom’s macroglobulinemia, it added.

Cadila Healthcare was quoting at Rs 465.05, up Rs 3.80, or 0.82 percent on the BSE.

News Source:- Moneycontrol

For Enquiry Fill The Form

*Note:- Please provide a valid Email Id to receive OTP from bigprofitbuzz.com.

Facebook Iconfacebook like buttonYouTube IconTwitter Icontwitter follow button